LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

210.02 0.36

Resumen

Variación precio

24h

Actual

Mínimo

205.05

Máximo

210.6

Métricas clave

By Trading Economics

Ingresos

-22M

-61M

Ventas

56M

214M

Margen de beneficio

-28.549

Empleados

1,017

EBITDA

-56M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+23.59% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.4B

13B

Apertura anterior

209.66

Cierre anterior

210.02

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

171 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 nov 2025, 22:42 UTC

Charlas de Mercado

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 nov 2025, 21:47 UTC

Charlas de Mercado

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov 2025, 21:43 UTC

Charlas de Mercado

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov 2025, 20:18 UTC

Charlas de Mercado

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov 2025, 20:14 UTC

Charlas de Mercado

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov 2025, 19:48 UTC

Charlas de Mercado

Precious Metals Fall for the Week -- Market Talk

21 nov 2025, 19:44 UTC

Ganancias

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov 2025, 19:37 UTC

Charlas de Mercado

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov 2025, 19:27 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

21 nov 2025, 19:27 UTC

Charlas de Mercado
Ganancias

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov 2025, 19:20 UTC

Charlas de Mercado

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov 2025, 18:44 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov 2025, 18:37 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov 2025, 18:34 UTC

Charlas de Mercado
Ganancias

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov 2025, 18:28 UTC

Ganancias

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 18:03 UTC

Charlas de Mercado

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov 2025, 17:24 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 nov 2025, 17:24 UTC

Charlas de Mercado

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 nov 2025, 17:05 UTC

Charlas de Mercado

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 nov 2025, 16:56 UTC

Charlas de Mercado

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 nov 2025, 16:47 UTC

Charlas de Mercado

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 nov 2025, 16:35 UTC

Adquisiciones, fusiones, absorciones

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 nov 2025, 16:09 UTC

Ganancias

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 15:59 UTC

Charlas de Mercado

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21 nov 2025, 15:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 nov 2025, 15:23 UTC

Charlas de Mercado

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21 nov 2025, 15:17 UTC

Charlas de Mercado

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

23.59% repunte

Estimación a 12 meses

Media 260.15 USD  23.59%

Máximo 325 USD

Mínimo 220 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

14

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

171 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat